Is BIOCRYST PHARMACEUTICALS INC (BCRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 20.6% / 30% | 12.9% / 30% | 5.0% / 30% | 1.22% / 5% | ✓ HALAL |
| DJIM | 20.6% / 33% | 12.9% / 33% | 5.0% / 33% | 1.22% / 5% | ✓ HALAL |
| MSCI | 85.4% / 33% | 53.4% / 33% | 20.8% / 33% | 1.22% / 5% | ✗ NOT HALAL |
| S&P | 20.6% / 33% | 12.9% / 33% | 5.0% / 33% | 1.22% / 5% | ✓ HALAL |
| FTSE | 85.4% / 33% | 53.4% / 33% | 20.8% / 50% | 1.22% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 79.1% | |
| Operating Margin | 65.6% | |
| Net Margin | 30.2% | |
| Return on Assets (ROA) | 43.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $347M |
| Free Cash Flow | $345M |
| Total Debt | $439M |
| Current Ratio | 2.1 |
| Total Assets | $514M |
Price & Trading
| Last Close | $9.56 |
| 50-Day MA | $7.77 |
| 200-Day MA | $7.90 |
| Avg Volume | 5.1M |
| Beta | 0.8 |
|
52-Week Range
$6.00
| |
About BIOCRYST PHARMACEUTICALS INC (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Purification Calculator
As a halal stock with 1.22% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BIOCRYST PHARMACEUTICALS INC (BCRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BIOCRYST PHARMACEUTICALS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BIOCRYST PHARMACEUTICALS INC's debt ratio?
BIOCRYST PHARMACEUTICALS INC's debt ratio is 20.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 85.4%.
Does BIOCRYST PHARMACEUTICALS INC require dividend purification?
Yes, BIOCRYST PHARMACEUTICALS INC has an impermissible income ratio of 1.22%, which means 1.22% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are BIOCRYST PHARMACEUTICALS INC's key financial metrics?
BIOCRYST PHARMACEUTICALS INC has a market capitalization of $2.3B, trailing P/E ratio of 7.7, and revenue of $875M. The company maintains a gross margin of 79.1% and a net margin of 30.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.